Computed tomography as a biomarker in clinical trials imaging

Journal of Thoracic Imaging

Volumn 28, Issue 5, 2013, Pages 291-297

  Goldin, Jonathan G ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

biomarker; chronic obstructive pulmonary disease; clinical trials; computed tomography; diffuse parenchymal lung disease

Indexed keywords

BIOLOGICAL MARKER;

AIRWAY REMODELING; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL DECISION MAKING; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; DENSITOMETRY; DISEASE COURSE; DISEASE SEVERITY; EMPHYSEMA; FORCED EXPIRATORY VOLUME; GOOD CLINICAL PRACTICE; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; IMAGE QUALITY; IONIZING RADIATION; LUNG FIBROSIS; LUNG FUNCTION; LUNG FUNCTION TEST; LUNG STRUCTURE; LUNG VOLUME; LUNG WEIGHT; OUTCOME ASSESSMENT; PATHOGENESIS; PHENOTYPE; PREDICTIVE VALUE; QUANTITATIVE ANALYSIS; RADIATION DOSE; SCLERODERMA; TOTAL LUNG CAPACITY; TREATMENT FAILURE; TREATMENT RESPONSE;

BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; HUMANS; LUNG DISEASES, INTERSTITIAL; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REPRODUCIBILITY OF RESULTS; TOMOGRAPHY, X-RAY COMPUTED; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84883687685     PISSN: 08835993     EISSN: 15360237     Source Type: Journal    
DOI: 10.1097/RTI.0b013e3182a1d93d     Document Type: Conference Paper

References (101)

1. Schuster DP. The opportunities and challenges of developing imaging biomarkers to study lung function and disease. Am J Respir Crit Care Med. 2007;176:224-230.
2. Barnes P, Chowdhury B, Kharitonov S, et al. Pulmonary biomarkers in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006;174:6-14.
3. U.S. Food and Drug Administration. March 2004 report: innovation or stagnation: challenge and opportunity on the critical path. Available at: http://www.fda.gov/oc/initiatives/criticalpath/. Accessed February 10, 2007.
4. Jones PW, Agusti AGN. Outcomes and markers in the assessment of chronic obstructive pulmonary disease. Eur Respir J. 2006;27:822-832.
5. Downing G, Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints. Clin Pharmacol Ther. 2001; 69:89-95.
6. Lee J, Devanarayan V, Barrett U, et al. Fit-for-purpose method development and validation for successful biomarker measurement. Pharm Res. 2006;23:312-328.
7. Frank R, Hargreaves R. Clinical biomarkers in drug discovery and development. Nat Rev Drug Discov. 2003;2:566-580.
8. Lesko L, Atkinson AJ. Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies. Annu Rev Pharmacol Toxicol. 2001;41:347-366.
9. Cazzola M, MacNee W, Martinez F, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J. 2008;31:416-469.
10. Bouros D, Antoniou KM. Current and future therapeutic approaches in idiopathic pulmonary fibrosis. Eur Respir J. 2005;25:1693-1702.
11. International Consensus (Joint) statement between the American Thoracic Society and the European Respiratory Society. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International Consensus Statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med. 2000;161:646-664.
12. Raghu G, Collard HR, Egan JJ, et al. An Official ATS/ERS/JRS/ALAT Statement: Idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788-824.
13. Johnson WC, Raghu G. Clinical trials in idiopathic pulmonary fibrosis: a word of caution concerning choice of outcome measures. Eur Respir J. 2005;26:755-758.
14. Woodruff PG. Novel outcomes and end-points: biomarkers in COPD clinical trials. Proc Am Thorac Soc. 2011;8:350-355.
15. Stoel BC, Vrooman HA, Stolk J, et al. Sources of error in lung densitometry with CT. Invest Radiol. 1999;34:303-309.
16. Best AC, Lynch AM, Bozic CM, et al. Quantitative CT indexes in idiopathic pulmonary fibrosis: relationship with physiologic impairment. Radiology. 2003;228:407-414.
17. Kemerink GJ, Lamers RJ, Thelissen GR, et al. Scanner conformity in CT densitometry of the lungs. Radiology. 1995; 197:749-752.
18. Parr DG, Stoel B, Stolk J, et al. The influence of BMI on lung CT densitometry in emphysema. Thorax. 2002;57:iii58.
19. Boedecker KL, McNitt-Gray MF, Rogers SR. Emphysema: effect of reconstruction algorithm on CT imaging 2004. Radiology. 2004;232:295-301.
20. Quantitative imaging biomarker alliance. Available at: http://qibawiki.rsna.org/index.php?title=COPD-Asthma-tech-ctte. Accessed April 29, 2012.
21. Levi C, Gray JE, McCullough EC, et al. The unreliability of CT numbers as absolute values. Am J Roentgenol. 1982;139: 443-447.
22. Kemerink GJ, Lamers RJ, Thelissen GR, et al. CT densitometry of the lungs: scanner performance. J Comput Assist Tomogr. 1996;20:24-33.
23. Parr DG, Stoel BC, Stolk J, et al. Influence of calibration on densitometric studies of emphysema progression using computed tomography. Am J Respir Crit Care Med. 2004; 170:83-890.
24. Kemerink GJ, Kruize HH, Lamers RJ, et al. CT lung densitometry: dependence of CT number histograms on sample volume and consequences for scan protocol comparability. J Comput Assist Tomogr. 1997;21:948-954.
25. McCullough EC. Specifying and evaluating the performance of computed tomography (CT) scanners. Med Phys. 1980; 7:291-296.
26. Judy P, San Jose Estepar R, Hoffman E. SU-FF-I-06: COPDGene Study Quality Assurance Phantom. Med Phys. 2009;36:2435.
27. Cameron JR. A radiation unit for the public. Phys Soc News. 1991;20:2.
28. Mayo JR, Aldrich J, Muller NL. Radiation exposure at chest CT: a statement of the Fleischner Society. Radiology. 2003;228:15-21.
29. Stoel BC, Bode F, Rames A, et al. Quality control in longitudinal studies with computed tomographic densitometry of the lungs. Proc Am Thorac Soc. 2008;5:929-933.
30. Regan EA, Hokanson JE, Murphy JR, et al. Genetic epidemiology of COPD (COPDGene) study design. COPD. 2010;7:32-43.
31. Subpopulations and intermediate outcome measures in COPD study (SPIROMICS). Available at: http://www. cscc.unc.edu/spir/. Accessed April 29, 2012.
32. The IPFnet Strategy. Creating a comprehensive approach in the treatment of idiopathic pulmonary fibrosis. Am J Respir Crit CareMed. 2010;181:527-528.
33. Guenther A. The European IPF Network: towards better care for a dreadful disease. Eur Respir J. 2011;37:744-772.
34. Shaker SB, Dirksen A, Laursen LC, et al. Volume adjustment of lung density by computed tomography scans in patients with emphysema. Acta Radiol. 2004;45:417-423.
35. Regan EA, Hokanson JE, Murphy JR, et al. Genetic epidemiology of COPD (COPDGene) study design. COPD. 2010;7:32-43, PMCID: 2924193.
36. Vestbo J, Andersen W, Coxon H. Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE). Eur Respir J. 2008;31:869-873.
37. Brown MS, McNitt-Gray MF, Pais R, et al. CAD in clinical trials: current role and architectural requirements. Comput Med Imaging Graph. 2007;31:332-337.
38. U.S. Food and Drug Administration. Guidance for Industrycomputerized systems used in clinical trials. Available at: http://www.fda.gov/ RegulatoryInformation/Guidances/ucm 126402.htm. Accessed April 29, 2012.
39. FDA. Guidance for Industry. Standards for Clinical Trial Imaging Endpoints: Developing Drugs for Treatment. Silver Spring, MD: U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER); 2011.
40. FDA. Guidance for Industry. Chronic Obstructive Pulmonary Disease: Developing Drugs for Treatment. Silver Spring, MD: U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER); 2007.
41. Paré PD, Camp PG. Airway disease and emphysema on CT: not just phenotypes of lung pathology. Thorax. 2012; 67:380-382.
42. Hayhurst MD, MacNee W, Flenley DC, et al. Diagnosis of pulmonary emphysema by computerised tomography. Lancet. 1984;2:320-322.
43. Guenard H, Diallo MH, Laurent F, et al. Lung density and lung mass in emphysema. Chest. 1992;102:198-203.
44. Haraguchi M, Shimura S, Hida W, et al. Pulmonary function and regional distribution of emphysema as determined by high-resolution computed tomography. Respiration. 1998; 65:125-129.
45. Heremans A, Verschakelen JA, Van Fraeyenhoven L, et al. Measurement of lung density by means of quantitative CT scanning. A study of correlations with pulmonary function tests. Chest. 1992;102:805-811.
46. Hartley PG, Galvin JR, Hunninghake GW, et al. Highresolution CT-derived measures of lung density are valid indexes of interstitial lung disease. J Appl Physiol. 1994; 76:271-277.
47. Rienmuller RK, Behr J, Kalender WA, et al. Standardized quantitative high resolution CT in lung diseases. J Comput Assist Tomogr. 1991;15:742-749.
48. Gould GA, MacNee W, McLean A, et al. CT measurements of lung density in life can quantitate distal airspace enlargement-an essential defining feature of human emphysema. Am Rev Respir Dis. 1988;137:380-392.
49. Gould GA, Redpath AT, Ryan M, et al. Lung CT density correlates with measurements of airflow limitation and the diffusing capacity. Eur Respir J. 1991;4:141-146.
50. Grydeland TB, Dirksen A, Coxson HO, et al. Quantitative computed tomography measures of emphysema and airway wall thickness are related to respiratory symptoms. Am J Respir Crit Care Med. 2010;181:353-359.
51. Grydeland TB, Thorsen E, Dirksen A, et al. Quantitative CT measures of emphysema and airway wall thickness are related to D(L)CO. Respir Med. 2011;105:343-351.
52. Mets OM, Buckens CF, Zanen P, et al. Identification of chronic obstructive pulmonary disease in lung cancer screening computed tomographic scans. JAMA. 2011;306:1775-1781.
53. Nakano Y, Muro S, Sakai H, et al. Computed tomographic measurements of airway dimensions and emphysema in smokers. Correlation with lung function. Am J Respir Crit Care Med. 2000;162:1102-1108.
54. Nakano Y, Sakai H, Muro S, et al. Comparison of low attenuation areas on computed tomographic scans between inner and outer segments of the lung in patients with chronic obstructive pulmonary disease: incidence and contribution to lung function. Thorax. 1999;54:384-389.
55. Dirksen A, Dijkman JH, Madsen IF, et al. A randomized clinical trial of a-1 antitrypsin augmentation therapy. Am J Respir Crit Care Med. 1999;160:1468-1472.
56. Parr DG, Stoel BC, Stolk J, et al. Pattern of emphysema distribution in alpha1-antitrypsin deficiency influences lung function impairment. Am J Respir Crit Care Med. 2004; 170:1172-1178.
57. Dirksen A, Piitulainen E, Parr DG, et al. Exploring the role of CT densitometry: a randomised study of augmentation therapy in alpha1-antitrypsin deficiency. Eur Respir J. 2009; 33:1345-1353.
58. Shaker SB, Dirksen A, Ulrik CS, et al. The effect of inhaled corticosteroids on the development of emphysema in smokers assessed by annual computed tomography. COPD. 2009;6: 104-111.
59. Yuan R, Hogg JC, Pare PD, et al. Prediction of the rate of decline in FEV(1) in smokers using quantitative computed tomography. Thorax. 2009;64:944-949.
60. Ashraf H, Lo P, Shaker SB, et al. Short-term effect of changes in smoking behaviour on emphysema quantification by CT. Thorax. 2011;66:55-60.
61. Brown MS, Kim HJ, Abtin FG, et al. Emphysema lung lobe volume reduction: effects on the ipsilateral and contralateral lobes. Eur Radiol. 2012;22:1547-1555.
62. Sciurba FC, Ernst A, Herth FJ, et al. A randomized study of endobronchial valves for advanced emphysema. N Engl J Med. 2010;363:1233-1244.
63. Herth F, Gompelmann D, Ernst A, et al. Endoscopic lung volume reduction. Respiration. 2010;79:5-13.
64. Gompelmann D. Study of Chartis System, and lack of fissure integrity assessed by CT imaging. Session 65: Presentation 373. European Respiratory Society Meeting Abstracts. 2011. Available at: http://www.erscongress2011.org.
65. Gompelmann D. Comparison between Chartis pulmonary assessment system detection of collateral ventilation vs Corelab CT fissure analysis for predicting atelectasis in emphysema patients treated with endobronchial valves. Session 390: Presentation 3565. European Respiratory Society Meeting Abstracts. 2011.
66. Koenigkam-Santos M, Paula WD, Gompelmann D, et al. Endobronchial valves in severe emphysematous patients: CT evaluation of lung fissures completeness, treatment radiological response and quantitative emphysema analysis. Radiol Bras. 2013;46:15-22. Available at: http://www.scielo.br/scielo. php?script=sci
67. Hogg JC, McDonough JE, Gosselink JV, et al. Review: what drives the peripheral lung-remodeling process in chronic obstructive pulmonary disease? Proc Am Thorac Soc. 2009; 6:668-672.
68. Niimi A, Matsumoto H, Amitani R, et al. Airway wall thickness in asthma assessed by computed tomography. Relation to clinical indices. Am J Respir Crit Care Med. 2000;162(pt 1):1518-1523.
69. Mikos M, Grzanka P, Sladek K, et al. High-resolution computed tomography evaluation of peripheral airways in asthma patients: comparison of focal and diffuse air trapping. Respiration. 2009;77:381-388.
70. Goldin JG, McNitt-Gray MF, Sorenson SM, et al. Airway hyperreactivity: assessment with helical thin-section CT. Radiology. 1998;208:321-329.
71. Gupta S, Siddiqui S, Haldar P, et al. Qualitative analysis of highresolution CT scans in severe asthma. Chest. 2009;136:1521-1528.
72. Zeidler MR, Goldin JG, Kleerup EC, et al. Small airways response to naturalistic cat allergen exposure in subjects with asthma. J Allergy Clin Immunol. 2006;118:1075-1081.
73. Zeidler MR, Kleerup EC, Goldin JG, et al. Montelukast improves regional air-trapping due to small airways obstruction in asthma. Eur Respir J. 2006;27:307-315.
74. Newell JD, Hogg JC, Snider GL. Report of a workshop: quantitative computed tomography scanning in longitudinal studies of emphysema. Eur Respir J. 2004;23:769-775.
75. Camiciottoli G, Bartolucci M, Maluccio NM, et al. Spirometrically gated high-resolution CT findings in COPD: lung attenuation versus lung function and dyspnea severity. Chest. 2006;129:558-564.
76. Washko GR, Parraga G, Coxon HO. Quantitative pulmonary imaging using computed tomography and magnetic resonance imaging. Respirology. 2012;17:432-444.
77. Castro SV, Jimenez S. Biomarkers in systemic sclerosis. Biomark Med. 2010;4:133-147.
78. Khanna D, Lovell DJ, Giannini PJ. Development of a provisional core set of response measures for clinical trials of systemic sclerosis. Ann Rheum Dis. 2008;67:703-709.
79. Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006;354:2655-2666.
80. Mathieson JR, Mayo JR, Staples CA, et al. Chronic diffuse infiltrative lung disease: comparison of diagnostic accuracy of CT and chest radiography. Radiology. 1989;171:111-116.
81. Hunninghake GW, Zimmerman MB, Schwartz DA, et al. Utility of a lung biopsy for the diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2001;164:193-196.
82. Raghu G, Mageto YN, Lockhart D, et al. The accuracy of the clinical diagnosis of new-onset idiopathic pulmonary fibrosis and other interstitial lung disease: a prospective study. Chest. 1999;116:1168-1174.
83. Grenier P, Valeyre D, Cluzel P, et al. Chronic diffuse interstitial lung disease: diagnostic value of chest radiography and high-resolution CT. Radiology. 1991;179:123-132.
84. Lee KS, Primack SL, Staples CA, et al. Chronic infiltrative lung disease: comparison of diagnostic accuracies of radiography and low-and conventional-dose thin-section CT. Radiology. 1994;191:669-673.
85. Swensen SJ, Aughenbaugh GL, Myers JL. Diffuse lung disease: diagnostic accuracy of CT in patients undergoing surgical biopsy of the lung. Radiology. 1997;205: 229-234.
86. Aalokken TM, Naalsund A, Mynarek G, et al. Diagnostic accuracy of computed tomography and histopathology in the diagnosis of usual interstitial pneumonia. Acta Radiol. 2012;53:296-302.
87. Lynch DA, William WD, Muller NL. Idiopathic interstitial pneumonias: CT features 5. Radiology. 2005;236:10-21.
88. Jeong YJ, Lee KS, Muller NL, et al. Usual interstitial pneumonia and non-specific interstitial pneumonia: serial thin-section CT findings correlated with pulmonary function. Korean J Radiol. 2005;6:143-152.
89. Kazerooni EA, Martinez FJ, Flint A, et al. Thin-section CT obtained at 10-mm increments versus limited three-level thin section CT for idiopathic pulmonary fibrosis: correlation with pathologic scoring. Am J Roentgenol. 1997;169:977-983.
90. Goh NSL, Desai SR, Veerarhagavan S, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med. 2008;177:1248-1254.
91. Beinert T, Kohz P, SeemannM, et al. Spirometrically controlled high resolution computed tomography: quantitative assessment of density distribution in patients with diffuse fibrosing alveolitis. Eur J Med Res. 1996;1:269-272.
92. Camiciottoli G, Orlandi I, Bartolucci M, et al. Lung CT densitometry in systemic sclerosis: correlation with lung function, exercise testing, and quality of life. Chest. 2007;131: 672-681.
93. Rodriguez LH, Vargas PF, Raff U, et al. Automated discrimination and quantification of idiopathic pulmonary fibrosis from normal lung parenchyma using generalized fractal dimensions in high resolution computed tomography images. Acad Radiol. 1995;2:10-18.
94. Kim HJ, Li G, Gjertson D, et al. Classification of parenchymal abnormality in scleroderma lung using a novel approach to denoise images collected via a multicenter study. Acad Radiol. 2008;15:1004-1016.
95. Best AC, Lynch AM, Bozic CM, et al. Quantitative CT indexes in idiopathic pulmonary fibrosis: relationship with physiologic impairment. Radiology. 2003;228:407-414.
96. Kim HJ, Brown MS, Elashoff R, et al. Quantitative texture-based assessment of one-year changes in fibrotic reticular patterns on HRCT in scleroderma lung disease treated with oral cyclophosphamide. Eur Radiol. 2011;21: 2455-2465.
97. Flaherty KR, Thwaite EL, Kazerooni EA, et al. Radiological versus histological diagnosis in UIP and NSIP: survival implications. Thorax. 2003;58:143-148.
98. Best AC, Meng J, Lynch AM, et al. Idiopathic pulmonary fibrosis: physiologic tests, quantitative CT indexes, and CT visual scores as predictors of mortality. Radiology. 2008;246: 935-940.
99. Goldin J, Elashoff R, Kim HY, et al. Treatment of scleroderma- interstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high-resolution CT scan than placebo. Chest. 2009;136: 1333-1340.
100. Raghu G, Scholand MB, Andrade J. Phase 2 trial of FG-3019, anti-CTGF monoclonal antibody, in idiopathic pulmonary fibrosis (IPF): Preliminary safety and efficacy results. European Respiratory Society Meeting Session 308: San Francisco, California; 2012. Available at: http://www.erseduc ation.org/ersMade/abstract-print-12/main-frameset.htm.
101. Shin KM, Lee KS, Chung MP, et al. Prognostic determinants among clinical, thin-section CT, and histopathologic findings for fibrotic idiopathic interstitial pneumonias: tertiary hospital study. Radiology. 2008;249:328-337.